Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gmbh

Pfizer Corporation

Merck Patent Gesellschaft

Claudia Wilm

Dieter Dorsch

Werner Mederski

Maria Christadler

Claus J Schmitges

Mathias Osswald

Simon Lawrence Goodman

Francesc Mitjans

Michael Gassen

Soheila Anzali

Heike Dahmen

Klaus Schneider

The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.

Diagnostic anti-PD-L1 antibody and use thereof

The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.

Antibodies for the detection of integrin complexes in FFPE material

Nkx2-C4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Nkx2-C4 polypeptides and polynucleotides in diagnostic assays.

NK-2 homeobox transcription factor

RGS8 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing RGS8 polypeptides and polynucleotides in diagnostic assays.

Regulator of G protein signalling

Benzothia(oxa)diazol derivatives and their use as endothelin-receptor antagonists

2,1,3-benzothia(OXA)diazole derivatives having an endothelin receptor

Endothelin receptor antagonists

Novel compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and X have the meaning indicated in claim 1, and their salts exhibit endothelin receptor-antagonistic properties.

Novel compounds of the formula I ##STR1## in which --Y--Z--, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings as stated in the specification, and their salts show endothelin receptor antagonist properties.

Novel compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, --A.dbd.B--C.dbd.D--, Ar and X have the meaning indicated in claim 1, and their salts show endothelin receptor-antagonistic properties.

Novel compounds of the formula ##STR1## in which --Y--Z--, R.sup.1 R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X have the meaning indicated and their salts show endothelin receptor-antagonistic properties.

Growing community of inventors

Darmstadt, Germany

Claudia Wilm